The first patient has been dosed in Gain Therapeutics‘ clinical trial of GT-02287, an investigational, oral small molecule being developed for treating Parkinson’s disease. With several locations open in Australia, the Phase 1b clinical trial (NCT06732180) is still recruiting up to 20 adults, ages 30-85, who’ve been…
News
Among people with rapid eye movement (REM) sleep behavior disorder, blood biomarkers associated with dementia may help identify those at risk of developing Dementia with Lewy Bodies (DLB), a condition that shares symptoms with Parkinson’s disease. Particularly, blood levels of two proteins — amyloid-beta 42/40 ratio and p-tau…
A rare nerve disorder may offer clues to potential Parkinson’s disease treatment targets, a mouse study showed. In giant axonal neuropathy (GAN), buildup of neurofilament proteins trap several cellular organelles and proteins, preventing nerve cells from clearing and recycling waste, the study found. Because neurofilament proteins have also been…
Right Brain Bio is repurposing the approved therapy RB-190 as a treatment for Parkinson’s disease — and is now preparing to seek U.S. Food and Drug Administration (FDA) clearance to test the anticancer medication for this indication in a Phase 2 clinical trial. The company intends to file…
An intervention combining talk therapy with virtual reality may help improve mental health and life quality for people with Parkinson’s disease, a study reports. “The results of this study demonstrated that [virtual reality-augmented cognitive behavioral therapy] significantly enhanced emotional well-being and quality of life in the experimental group compared…
Rare mutations that impair the normal activity of the ITSN1 gene were found to increase the risk of Parkinson’s disease by about 10 times, according to a study. The findings are in line with those of another recent study that linked ITSN1 mutations to an elevated Parkinson’s risk,…
An adapted physical activity program may help ease motor symptoms of Parkinson’s disease, a study showed. Although patients’ motor symptoms eased immediately after the three-month program, there didn’t appear to be a long-term effect on motor symptom severity, emphasizing a need for longer programs and/or further resources to…
Note: This story was updated March 17, 2025, to correct the attribution of quotes to Sonya Dumanis, PhD, deputy director of Aligning Science Across Parkinson’s. The Aligning Science Across Parkinson’s (ASAP) initiative is investing $6 million in research grants to support the development of new tools — including cell…
Boosting levels of a protein called TFE3 helped reduce nerve cell degeneration and improve motor function in a mouse model of Parkinson’s disease, a study found. Increased levels of this protein helped clear toxic alpha-synuclein clumps, a hallmark of Parkinson’s, as well as restore the function of mitochondria, the…
People with obstructive sleep apnea (OSA) are at increased risk of developing Parkinson’s disease, but starting treatment with continuous positive airway pressure — with the use of a CPAP machine — within two years of an OSA diagnosis can reduce that risk, new research suggests. “While our study found…
Recent Posts
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s
- Trial testing Crexont for advanced Parkinson’s kicks off in Europe